Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Augsburger, F
With its FDA approval and a unique dual-action mechanism that targets both appetite regulation and glucose metabolism, it stands as a powerful ally in the battle against obesity
Another 2025 review revealed that injection-site reactions are more likely with tirzepatide than with semaglutide (but keep in mind these reactions are almost always mild and temporary)
Studies show that adding a GLP-1 to insulin therapy can reduce insulin requirements by 20-50%, meaning your current dose may cause dangerously low blood sugar without adjustment
Mild symptoms may improve, but severe or persistent nausea deserves clinical review
*Compounded semaglutide and tirzepatide are not FDA-approved, are not generic versions of FDA-approved drugs like Ozempic, Wegovy, Mounjaro, or Zepbound, and are not reviewed by FDA for safety, effectiveness, or quality
